PerkinElmer combines Life Science and Analytical Instrument businesses. (Executive Briefing).
After the business integration following the acquisition of Packard Bioscience, PerkinElmer Life Science is set for another reorganization. As for the analytical instruments business, the move raises questions as to the attention and resources some product lines will receive from the new unit. However, the division's products for the biotech and pharma markets can be expected to flourish within the new division. In its quarterly conference call, PerkinElmer said it expects the consolidation to save $45 million in SG&A expenses.
|Printer friendly Cite/link Email Feedback|
|Publication:||Instrument Business Outlook|
|Article Type:||Brief Article|
|Date:||Oct 31, 2002|
|Previous Article:||Harvard Bioscience sticks to its strategy.|
|Next Article:||Enzo Biochem files suit against eight Life Science companies. (Executive Briefing).|